Dexdor: a new hospital-only sedative

Continuous cardiac monitoring is required during dexmedetomidine infusion | SCIENCE PHOTO LIBRARY
Continuous cardiac monitoring is required during dexmedetomidine infusion | SCIENCE PHOTO LIBRARY

Dexdor (dexmedetomidine) is licensed for adult patients in intensive care who require sedation not deeper than arousal in response to verbal stimulation (corresponding to Richmond Agitation-Sedation Scale (RASS) 0 to -3).

Dexmedetomidine is a selective alpha-2 receptor agonist. It exerts its sedative effect through decreased firing of the locus coeruleus, the predominant noradrenergic nucleus in the brainstem. Dexmedetomidine has minimal respiratory depressive effects.

Dexdor must be given by intravenous infusion using a controlled infusion device.

View Dexdor drug record

Further information: Orion

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

An elderly woman with one arm in a plaster cast sits resting both hands on her walker

Doctors urge NICE to reverse decision on new osteoporosis drug

More than NHS 100 clinicians have called on NICE to...

Drug shortages - live tracker

Use our constantly updated shortages tracker to check...

Image of both strengths of Seffalair Spiromax inhaler side by side.

New salmeterol/fluticasone dry powder inhaler for asthma

Seffalair Spiromax is the sixth dry powder salmeterol/fluticasone...

An older man in a blue shirt and beige trousers leans forward on a sofa rubbing his painful lower back. Promoted
MIMSconnect

Established muscle relaxant offers new approach to managing back pain

Sponsored by Mibe Pharma

A muscle relaxant that has been used for decades outside the UK may provide an alternative to current treatments for low back pain, explains Dr Sunny Nayee, consultant in anaesthesia and pain medicine at Imperial College NHS Healthcare Trust.

Sponsored by Mibe Pharma UK Ltd. UK/MYO/21/044; December 2021.

Click here to view prescribing information for Myopridin® (pridinol mesilate)